Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23346006 | 0.88 | HDAC4 (0.53) | AOC3L3MBTL1CYP3A4 | |
| SCHEMBL11604883 | 0.87 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL2093768 | 0.87 | AOC3 (0.59) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL43735 | 0.85 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL43520 | 0.85 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL343726 | 0.85 | AOC3 (0.57) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL17295984 | 0.83 | AOC3 (0.56) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL18896729 | 0.83 | AOC3 (0.60) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6202883 | 0.83 | AOC3 (0.56) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6204866 | 0.83 | AOC3 (0.56) | AOC3L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720222-A1 | CONTROL OF PYROLYSIS CONDITIONS FOR THE PRODUCTION OF DESIRABLE COMPOUNDS | Talipot Cool Extract (IP), LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250072428-A1 | CONTROL OF PYROLYSIS CONDITIONS FOR THE PRODUCTION OF DESIRABLE COMPOUNDS | TALIPOT COOL EXTRACT (IP), LLC | 2025-03-06 | — | — | US | disclosed |
| WO-2024249937-A1 | CONTROL OF PYROLYSIS CONDITIONS FOR THE PRODUCTION OF DESIRABLE COMPOUNDS | TALIPOT COOL EXTRACT (IP), LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-111499601-B | Preparation method and application of AHL signal molecule | 浙江海洋大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20220315895-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | IMMUNEBRIDGE LLC | 2022-10-06 | — | — | US | disclosed |
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2399584-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-5763681-A | ALPHA-2-ADAMANTYLIDENE-ALPHA-METHOXY-META-METHOXYTOLUENE AND RELATED COMPOUNDS AS INTERMEDIATES | TROPIX, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5225584-A | Phosphonate esters and trialkylsilyl phosphonate esters | TROPIX, INC. (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0441948-A4 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | — | 1992-06-03 | — | — | EP | disclosed |
| EP-0238753-B1 | N-SUBSTITUTED CONDENSED POLYMETHYLENE IMINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-01-15 | — | — | EP | disclosed |
| EP-0441948-A1 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | TROPIX, INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| WO-1991003479-A1 | SYNTHESIS OF STABLE, WATER-SOLUBLE CHEMILUMINESCENT 1,2-DIOXETANES AND INTERMEDIATES THEREFOR | TROPIX, INC. (US) | 1991-03-21 | — | — | WO | disclosed |
| US-4959374-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, GLAUCOMA, HYPERGLYCEMIC AGENTS, ANTIDEPRESSANTS | BEECHAM GROUP P.L.C. (GB) | 1990-09-25 | — | — | US | disclosed |
| US-4863946-A | HYPOGLYCEMIC AND HYPOTENSIVE AGENTS | BEECHAM GROUP PLC (GB) | 1989-09-05 | — | — | US | disclosed |
| EP-0238753-A1 | N-substituted condensed polymethylene imine derivatives | BEECHAM GROUP PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
| US-4298762-A | OPPENAUER OXIDATION USING FURFURAL AS HYDROGEN ACCEPTOR | SCM CORPORATION (US) | 1981-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315895-A1 | METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS | MCL1, CD14, ICOS | AOC3 948/4885L3MBTL1 736/4885CHRM2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.